Cytochemical investigation of neutral proteases in polymorphonuclear (PMN) neutrophils in acute inflammatory diseases

1980 ◽  
Vol 69 (3) ◽  
pp. 307-314 ◽  
Author(s):  
C. Klessen ◽  
W. Tekolf
2020 ◽  
Author(s):  
Ewa Dudzińska ◽  
Aneta Strachecka ◽  
Paulina Gil-Kulik ◽  
Janusz Kocki ◽  
Jacek Bogucki ◽  
...  

Abstract Introduction: There is growing evidence that intestinal proteases have a role in the pathogenesis of gastrointestinal inflammatory diseases. IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC), has an additional source of proteases represented by infiltrated and activated inflammatory cells. The aim of our study was to determine proteolytic system activity in patients with CD and UC. We limited the number of proteases tested by determining proteases active in acidic, neutral and alkaline pH.Material and methods: The study included 40 patients with IBD – 20 CD patients and 20 UC patients. Among the 20 CD patients, 17 were treated with aminosalicylates, 14 with azathioprine, and 4 with corticosteroids, while 8 patients were undergoing biological treatment. Among the 20 UC patients, 19 were treated with aminosalicylates, 8 with azathioprine, and 3 with corticosteroids. The optimal pH in which the enzymes were active was determined in acidic, neutral, and alkaline buffer environments. We prepared buffers of defined pH from 2.2 to 12.8, separated by 0.2 intervals and then determined proteolytic activity against substrates (gelatine, haemoglobin, ovalbumin, albumin, cytochrome C, and casein). Results: A decrease was observed in the activity of acid proteases (pH 5), alkaline proteases (pH 7), and neutral proteases (pH 7.6 and 8.6) in the groups of CD patients in remission in comparison with the active phase. In the group of patients with CD treated biologically, acid protease activity (pH 5.0) was lower than in CD patients not receiving biological treatment.Activity of neutral (pH 7.0) and alkaline (pH 7.6 and 8.6) proteases in the plasma of patients with UC in remission were lower in comparison to the active phase.Activity of acid (pH 5.0) and alkaline (8.6) protease inhibitors was higher in CD patients in the active phase in comparison to remission. In UC patients with exacerbation of the disease, the activity of alkaline (pH 8.6) protease inhibitors was increased compared to remission.Conclusions: 1. Our research may suggest that the immunomodulatory treatment used in IBD, aimed at reducing the level of leukocytes, may contribute to a reduction in protease activity.2. The decrease in the level of proteases in patients with CD and UC in remission may be a marker suggesting the patients’ response to the treatment.


1993 ◽  
Vol 26 (4) ◽  
pp. 639-655 ◽  
Author(s):  
James A. Stankiewicz ◽  
David J. Newell ◽  
Albert H. Park

1997 ◽  
Vol 12 (3) ◽  
pp. 212-222 ◽  
Author(s):  
W.D. Schoenherr ◽  
Dennis E. Jewell

2000 ◽  
Vol 39 (08) ◽  
pp. 218-231 ◽  
Author(s):  
F. Grünwald ◽  
T. Kuwert ◽  
K. Tatsch ◽  
O. Sabri ◽  
O. Benkert ◽  
...  

SummaryThis article gives in his second part a critical review of the clinical applications of SPECT with perfusion markers and receptor ligands in dementing disorders and psychosis. In addition this review discusses clinical applications of SPECT investigations with perfusion markers in inflammatory diseases of the central nervous system and in brain trauma.


1996 ◽  
Vol 16 (01) ◽  
pp. 56-59
Author(s):  
D. J. Tyrrell ◽  
C. P. Page

SummaryEvidence continues to accumulate that the pleiotropic nature of heparin (beyond its anticoagulant potency) includes anti-inflammatory activities at a number of levels. It is clear that drugs exploiting these anti-inflammatory activities of heparin may offer exciting new therapeutic applications to the treatment of a wide range of inflammatory diseases.


Sign in / Sign up

Export Citation Format

Share Document